The Society of Nuclear Medicine and Molecular Imaging said the move denies patients access to potentially lifesaving technologies.

Biopharmaceutical firm Attralus has completed a $25 million Series A financing designed to further validate its AT-01 pan-amyloid radiotracer for PET/CT.

Researchers monitored how the heart and kidneys responded one day, three days, seven days and six weeks following an induced myocardial infarction. 

The president of the American Society of Nuclear Cardiology said there are no shortfalls reported at this time, but the organization is keeping an eye on the situation as more countries implement travel bans.

“We anticipate that these expert multisocietal consensus recommendations on multimodality imaging in cardiac amyloidosis will standardize the diagnosis and improve the management of this highly morbid and underdiagnosed disease," wrote authors of the new guidelines published in the Journal of Nuclear Cardiology.

Multiple nuclear medicine and cardiology groups are working to oppose potential cuts to myocardial PET scans that were made possible by the CMS 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, according to a joint statement.

When CMS released the 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, it included revisions that could lead to technical component payment reductions of up to 80% for certain services related to myocardial PET scans.

Janesville, Wisconsin-based SHINE Medical Technologies has announced an agreement with the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), gaining exclusive rights over an innovation to produce lutetium-177 (Lu-177).